Genomic Allergen Rapid Detection

In Vitro Skin Sensitisation Assay (GARD^TM) Genomic Allergen Rapid Detection

This is one of four test methods (DPRA, KeratinoSens^TM and h-CLAT) for the assessment of skin sensitisation potential.

Assessment of skin sensitisation potential with the GARD^TM

• The third molecular key event of skin sensitisation addresses the activation of dendritic cells (DC), which is typically accompanied by expression of specific cell surface markers, chemokines and cytokines.

• The GARD^TM assay can be performed to predict the ability of chemicals to induce skin sensitisation based on the analysis of relative expression levels of a biomarker signature of 196 genes. These biomarkers represent the various activated mechanisms in dendritic cells (DCs) in response to chemicals. The test method uses SenzaCell, a human myeloid leukemia cell line. This cell line works as an in vitro model of human dendritic cells and chemical stimulation of the cells can be assessed.
• With this test method transcriptional quantification of the genomic predictors, termed collectively the GARD^TM Prediction Signature (GPS), using a Nanostring nCounter technology can be determined. Based on a derived decision value (DV) from a Support Vector Machine (SVM) model chemicals can be predicted to be sensitisers or non-sensitisers. The algorithm of this machine uses known data sets from already done cell stimulations with known chemicals. Using this data set for each new chemical a decision value is created and the mean value is used for classification. A sensitising chemical can be further classified into category 1A or 1B.
• All experimental steps until the isolation of the RNA are performed at Eurofins. The qualification of the RNA and the Nanostring endpoint measurement are performed in cooperation with SenzaGen AB in Sweden.
• In combination with other complementary information within an Integrated Approach to Testing and Assessment (IATA) or as a stand-alone method, the GARD^TM Assay can be used as a reliable in vitro method to assess skin sensitising potential of chemicals.

Procedure

Principles of the GARD^TM Assay

References

1. The OECD (2012), The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. Part 1: Scientific Evidence. Series on Testing and Assessment No. 168

2. UN (2015), United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Sixth revised edition, UN New York and Geneva

Kontakt

Direct Peptide Reactivity Assay (DPRA)

KeratinoSens^TM

Human Cell Line Activation Test (h-CLAT)

Genomic Allergen Rapid Detection (GARD TM)

in vitro Skin Irritaion

in vitro Skin Irritation of Medical Devices

Skin Corrosion

Genotoxicity Testing

'Genetic toxicology: choosing the right testing strategy'

Chromosome Aberration Test

HPRT Assay